Ladies and Gents, I am in GCKO with you, and believe the company has great promise. But I must say I am disappointed with the biomed report. I am closely associated with Contract Manufacturing for a fortune 20 company, and this news is very, very preliminary. I would not consider the preparation necessary to submit an RFQ to a contract manufacturer as newsworthy at all. And I am long the stock, folks. Great company, great promise, but announcing that your CM is in receipt of your bill of materials and will soon be quoting a price? This isn't even good sourcing strategy- the CM should assume they are competing for the business. Think the price to GCKO just went down based on Spartan reading the article? They now know they have more leverage with GCKO. Imagine if they told GCKO 'no thanks'. And all of this before they have run a single manufacturing trial, done a single DFM review, anything? I'm sorry, but this is a true pump folks.
Market Data 
Markets 
AI
